30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Exactech

4Q13 revenue: $61.6MM, +4% (U.S. $41.8MM, +9%; ex-U.S. $19.8MM, -5%)

  • Hips $10.1MM, -2%
  • Knees $20.4MM, -2%
  • Biologic & Spine $6.6MM, +3%
  • Extremity $18.4MM, +24%
  • Other $6.0MM, -13%

 

  • Medical device tax $0.5MM in 4Q

 

2013 revenue: $237.1MM, +6% (U.S. $159.7MM, +10%; ex-U.S. $77.4MM, -2%)

  • Hips $41.0MM, +0.3%
  • Knees $80.5MM, -1%
  • Biologic & Spine $25.5MM, +4%
  • Extremity $65.5MM, +26%
  • Other $24.6MM, -4%

 

  • Ex-U.S. sales growth impacted by ceased distribution of 3rd-party products in certain regions, price pressure, currency (knee particularly affected by pricing/currency)
  • Spine growth supported by increased share with existing customers + “a few new customers”
  • Increased number of active trials of Exactech GPS Guided Personalization System, driving new knee sales
  • Engaged in VuMedi seminar for surgeon education on shoulder product
  • Launched bone- and neck-conserving hip stem in 1Q14
  • Wedge-style primary hip slated to commence surgeries in 2H14
  • Developing revision hip system for potential launch in late 2015
  • Presently ~260 sales reps in 38 U.S. sales agencies
  • On track with UDI implementation plans